Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis
Johann E. Gudjonsson, … , Robert L. Modlin, Errol P. Prens
Johann E. Gudjonsson, … , Robert L. Modlin, Errol P. Prens
Published August 27, 2020
Citation Information: JCI Insight. 2020;5(19):e139930. https://doi.org/10.1172/jci.insight.139930.
View: Text | PDF
Research Article Dermatology Immunology

Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis

  • Text
  • PDF
Abstract

Hidradenitis suppurativa (HS) is a debilitating chronic inflammatory skin disease characterized by chronic abscess formation and development of multiple draining sinus tracts in the groin, axillae, and perineum. Using proteomic and transcriptomic approaches, we characterized the inflammatory responses in HS in depth, revealing immune responses centered on IFN-γ, IL-36, and TNF, with lesser contribution from IL-17A. We further identified B cells and plasma cells, with associated increases in immunoglobulin production and complement activation, as pivotal players in HS pathogenesis, with Bruton’s tyrosine kinase (BTK) and spleen tyrosine kinase (SYK) pathway activation as a central signal transduction network in HS. These data provide preclinical evidence to accelerate the path toward clinical trials targeting BTK and SYK signaling in moderate-to-severe HS.

Authors

Johann E. Gudjonsson, Lam C. Tsoi, Feiyang Ma, Allison C. Billi, K.R. van Straalen, A.R.J.V. Vossen, H.H. van der Zee, Paul W. Harms, Rachael Wasikowski, Christine M. Yee, Syed M. Rizvi, Xianying Xing, Enze Xing, Olesya Plazyo, Chang Zeng, Matthew T. Patrick, Margaret M. Lowe, Richard E. Burney, Jeffrey H. Kozlow, Jill R. Cherry-Bukowiec, Yanyun Jiang, Joseph Kirma, Stephan Weidinger, Kelly C. Cushing, Michael D. Rosenblum, Celine Berthier, Amanda S. MacLeod, John J. Voorhees, Fei Wen, J. Michelle Kahlenberg, Emanual Maverakis, Robert L. Modlin, Errol P. Prens

×

Figure 1

Characterization of the inflammatory process in HS by RNA-Seq is suggestive of heightened B cell responses.

Options: View larger image (or click on image) Download as PowerPoint
Characterization of the inflammatory process in HS by RNA-Seq is suggest...
PCA plots of skin (top, red), and blood (bottom, blue) in patients with HS (n = 22) and healthy controls (n = 10) (A). Comparison of fold change mRNA expression of key proinflammatory cytokines in HS compared with psoriasis and AD (n = 22 HS, n = 28 psoriasis, n = 32 AD). Medians are shown in the middle of each plot. (B). Comparison of key proinflammatory cytokine responses in HS skin compared with psoriasis and AD. (n = 22 HS, n = 28 psoriasis, n = 32 AD) (red bar indicates baseline responses in uninflamed control skin) (C). Comparison of DEGs in HS skin against psoriasis (n = 28) and AD (n = 32). Unique genes in HS are shown in red, genes unique to psoriasis or AD are shown in green, and genes significant in both are shown in blue (D). Enriched B cell signatures in skin of patients with HS but T cell responses in blood of patients with HS (E). Enriched biological processes and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in increased (top) and decreased (bottom) DEGs in HS skin (F).

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts